Theravance Biopharma, Inc.
TBPHUS売上高
$107M
百万USD
営業利益
$-4M
百万USD
純利益
$106M
百万USD
ROE
35.7%
最新FY
EPS
$2.06
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $14M | $-80M | - |
| FY2021 | Q2 | $13M | $-52M | - |
| FY2021 | Q3 | $13M | $-35M | $-0.48 |
| FY2021 | FY | $55M | $-199M | $-2.87 |
| FY2022 | Q1 | $13M | $-26M | $-0.65 |
| FY2022 | Q2 | $11M | $-8M | $-0.11 |
| FY2022 | Q3 | $12M | $917M | $12.14 |
| FY2022 | FY | $51M | $872M | $11.85 |
| FY2023 | Q1 | $10M | $-22M | $-0.35 |
| FY2023 | Q2 | $14M | $-16M | $-0.28 |
| FY2023 | Q3 | $16M | $-9M | $-0.17 |
| FY2023 | FY | $57M | $-55M | $-1.00 |
| FY2024 | Q1 | $15M | $-12M | $-0.24 |
| FY2024 | Q2 | $14M | $-17M | $-0.34 |
| FY2024 | Q3 | $17M | $-13M | $-0.26 |
| FY2024 | FY | $64M | $-56M | $-1.15 |
| FY2025 | Q1 | $15M | $-14M | $-0.27 |
| FY2025 | Q2 | $26M | $55M | $1.08 |
| FY2025 | Q3 | $20M | $4M | $0.07 |
| FY2025 | FY | $107M | $106M | $2.06 |
| FY2026 | Q1 | $18M | $-5M | $-0.10 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $60M | $73M | $72M | $55M | $51M | $57M | $64M | $107M |
| 営業利益 | $-180M | $-260M | $-239M | $-252M | $-298M | $-258M | $-92M | $-56M | $-47M | $-4M |
| 純利益 | $-191M | $-285M | $-216M | $-236M | $-278M | $-199M | $872M | $-55M | $-56M | $106M |
| 総資産 | $639M | $441M | $560M | $409M | $469M | $375M | $607M | $382M | $354M | $486M |
| 純資産 | - | - | - | - | - | - | - | - | - | $297M |
| 自己資本 | $350M | $115M | $-52M | $-224M | $-304M | $-339M | $442M | $213M | $176M | $297M |
| 営業CF | - | $-201M | $-113M | $-238M | $-250M | $-208M | $-187M | $-27M | $-12M | $239M |
| EPS | - | - | - | - | - | $-2.87 | $11.85 | $-1.00 | $-1.15 | $2.06 |
| BPS | $6.63 | $2.12 | $-0.93 | $-3.58 | $-4.72 | $-4.53 | $7.03 | $4.42 | $3.55 | $5.76 |
| ROE | -54.4% | -247.8% | 417.8% | 105.6% | 91.5% | 58.9% | 197.4% | -25.9% | -32.1% | 35.7% |